Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles

Nanomedicine

Volumn 8, Issue 5, 2013, Pages 687-698

  Valencia, Pedro M ^a   Pridgen, Eric M ^a   Perea, Brian ^b   Gadde, Suresh ^c   Sweeney, Christopher ^d   Kantoff, Philip W ^d   Bander, Neil H ^e   Lippard, Stephen J ^f   Langer, Robert ^a,f   Karnik, Rohit ^a   Farokhzad, Omid C ^c,f  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b Arizona State University   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

cisplatin; combination chemotherapy; irinotecan; nanoparticle; PSMA

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE; IRINOTECAN; MACROGOL; NANOPARTICLE; POLY(LACTIDE CO GLYCOLIDE) CO POLY(ETHYLENE GLYCOL); POLYGLACTIN; POLYMER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DRUG CONJUGATION; DRUG DNA BINDING; DRUG POTENTIATION; DRUG TARGETING; HYDRODYNAMICS; INTERNALIZATION; MICROFLUIDICS; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; SYNTHESIS;

ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NANOPARTICLES; POLYMERS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84877680982     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.134     Document Type: Article

References (35)

1. Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5(1), 65-72 (2005).
2. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8(2), 111-128 (2009).
3. Lehar J, Krueger AS, Avery W et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27(7), 659-666 (2009).
4. Mayer LD, Harasym TO, Tardi PG et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5(7), 1854-1863 (2006).
5. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7(8), 573-584 (2007).
6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4(4), 307-320 (2005).
7. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107(5), 1387-1407 (2007).
8. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8(3), 641-661 (2002).
9. Tardi PG, Dos Santos N, Harasym TO et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol. Cancer Ther. 8(8), 2266-2275 (2009).
10. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85-91 (2002).
11. Hanna N, Bunn PA Jr, Langer C et al. Randomized Phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24(13), 2038-2043 (2006).
12. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
13. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res. 44(10), 1123-1134 (2011).
14. Hrkach J, Von Hoff D, Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128ra39 (2012).
15. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41(7), 2971-3010 (2012).
16. Hu C, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1(2), 323-334 (2010).
17. Kolishetti N, Dhar S, Valencia PM et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl Acad. Sci. USA 107(42), 17939-17944 (2010).
18. Maresca KP, Hillier SM, Femia FJ et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J. Med. Chem. 52(2), 347-357 (2009).
19. Hillier SM, Maresca KP, Femia FJ et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 69(17), 6932-6940 (2009).
20. Cheng J, Teply BA, Sherifi I et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869-876 (2007).
21. Karnik R, Gu F, Basto P et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 8(9), 2906-2912 (2008).
22. Valencia PM, Basto PA, Zhang L et al. Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano 4(3), 1671-1679 (2010).
23. Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol. Ther. 7(6), 974-982 (2008).
24. Thomas M, Kularatne SA, Qi L et al. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci. 1175, 32-39 (2009).
25. Kularatne SA, Wang K, Santhapuram HK, Low PS. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 6(3), 780-789 (2009).
26. Zastre J, Anantha M, Ramsay E, Bally M. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother. Pharmacol. 60(1), 91-102 (2007).
27. Gu FX, Karnik R, Wang AZ et al. Targeted nanoparticles for cancer therapy. Nano Today 2(3), 14-21 (2007).
28. Valencia PM, Hanewich-Hollatz MH, Gao W et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 32(26), 6226-6233 (2011).
29. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 105(45), 17356-17361 (2008).
30. Rhee M, Valencia PM, Rodriguez MI, Langer R, Farokhzad OC, Karnik R. Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannels. Adv. Mater. 23(12), H79-H83 (2011).
31. Vauthier C, Schmidt C, Couvreur P. Measurement of the density of polymeric nanoparticulate drug carriers by isopycnic centrifugation. J. Nanoparticle Res. 1, 411-418 (1999).
32. Johnson BK, Prud'homme RK. Mechanism for rapid self-assembly of block copolymer nanoparticles. Phys. Rev. Lett. 91(11), 118302 (2003).
33. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 1(4), 321-333 (2004).
34. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58(3), 621-681 (2006).
35. Reese DM, Tchekmedyian S, Chapman Y, Prager D, Rosen PJ. A Phase II trial of irinotecan in hormone-refractory prostate cancer. Invest. New Drugs 16(4), 353-359 (1998).